Supplementary Figure 5 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer

Supplementary Figure 5. Combined use of RMC4550 with alectinib, crizotinib or osimertinib Immunoblots of the indicated proteins in H3122 and ABC-19 cells treated with alectinib (Alec, 100 nM), HCC78 and ABC-20 cells treated with crizotinib (Cri, 1 µM) and PC-9 and HCC827 cells treated with osimertinib (Osi, 100 nM). All cell lines were also treated with RMC-4550 (RMC, 5 µM). Comb, combination. (B) Cell viability curves plotted for the cell lines treated with the molecular-targeted drug alone (circles), RMC-4550 alone (triangles) or the molecular-targeted drug and RMC-4550 (5 µM) (squares). All drugs were loaded for 96 h. Error bars represent the standard error.